A single low dose of eribulin regressed a highly aggressive triple-negative breast cancer in a patient-derived orthotopic xenograft model

Hye In Lim, Jun Yamamoto, Sachiko Inubushi, Hiroto Nishino, Yoshihiko Tashiro, Norihiko Sugisawa, Quinhong Han, Yu Sun, Hee Jun Choi, Seok Jin Nam, Moon Bo Kim, Ji Sun Lee, Chihiro Hozumi, Michael Bouvet, Shree Ram Singh, Robert M. Hoffman

研究成果: Article査読

5 被引用数 (Scopus)

抄録

Background/Aim: In the present study, the breast cancer patient-derived orthotopic xenograft (PDOX) model was used to identify an effective drug for a highly aggressive triple negative breast cancer (TNBC). Materials and Methods: The TNBC tumor from a patient was implanted in the right 4th inguinal mammary fat pad of nude mice to establish a PDOX model. Three weeks later, 19 mice were randomized into the untreated-control group (n=10) and the eribulin treatment group (n=9, eribulin, 0.3 mg/kg, i.p., day 1). Results: On day 8, eribulin significantly inhibited tumor volume compared to the control group (p<0.01). Eribulin regressed tumors in 3 mice (33.3%) and apparently eradicated them in 6 mice (66.7%). At day 14, tumor regrowth was observed in 2 mice of the eribulin group, which was undetectable on day 8. However, 44.4% (4 out of 9) of the mice in the eribulin group were tumor-free on day 14. Conclusion: A single low-dose eribulin was efficacious on a highly aggressive TNBC. The breast cancer PDOX model can be used to identify highly effective drugs for TNBC.

本文言語English
ページ(範囲)2481-2485
ページ数5
ジャーナルAnticancer research
40
5
DOI
出版ステータスPublished - 2020 5月
外部発表はい

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究

フィンガープリント

「A single low dose of eribulin regressed a highly aggressive triple-negative breast cancer in a patient-derived orthotopic xenograft model」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル